Magazine Article | February 1, 2021

Thrust Into A New Fundraising Norm

Source: Life Science Leader

By Matthew Pillar, Editor, BioProcess Online

By the time Randy Schatzman, Ph.D., was the guest on The Business of Biotech podcast, his company, Bolt Biotherapeutics, already had closed a $93 million Series C round of financing in the early months of the COVID pandemic. The CEO had joined Bolt, which focuses on immuno-oncology drug discovery and development, only a year prior.

VIEW THE MAGAZINE ARTICLE!
Signing up provides unlimited access to:
Signing up provides unlimited access to:
  • Trend and Leadership Articles
  • Case Studies
  • Extensive Product Database
  • Premium Content
HELLO. PLEASE LOG IN. X

Not yet a member of Life Science Leader? Register today.

ACCOUNT SIGN UP X
Please fill in your account details
Login Information
I'm interested in newsletter subscriptions.
ACCOUNT SIGN UP

Subscriptions

Sign up for the newsletter that brings you the industry's latest news, technologies, trends and products.

You might also want to: